Yahoo · Nov 6, 2026
Entera Announces Third Quarter 2026 Financial Results and Business Updates
Clinical Preparations Advanced for EB613 Phase 3 Osteoporosis Study, with First Site Activation Expected in Late 2026 Clinical and Commercial Leadership Expanded with Appointment of Senior Executives and Directors EB613 Enhanced Anabolic Effect Highlighted at ASBMR Plenary Poster Presentation IND-Enabling Activities Ongoing for EB612, in Development with OPKO for Hypoparathyroidism Tel Aviv, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in

